Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin - PubMed (original) (raw)

Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin

T Sasaki et al. EMBO J. 1998.

Abstract

The C-terminal domain NC1 of mouse collagen XVIII (38 kDa) and the shorter mouse and human endostatins (22 kDa) were prepared in recombinant form from transfected mammalian cells. The NC1 domain aggregated non-covalently into a globular trimer which was partially cleaved by endogenous proteolysis into several monomers (25-32 kDa) related to endostatin. Endostatins were obtained in a highly soluble, monomeric form and showed a single N-terminal sequence which, together with other data, indicated a compact folding. Endostatins and NC1 showed a comparable binding activity for the microfibrillar fibulin-1 and fibulin-2, and for heparin. Domain NC1, however, was a distinctly stronger ligand than endostatin for sulfatides and the basement membrane proteins laminin-1 and perlecan. Immunological assays demonstrated endostatin epitopes on several tissue components (22-38 kDa) and in serum (120-300 ng/ml), the latter representing the smaller variants. The data indicated that the NC1 domain consists of an N-terminal association region (approximately 50 residues), a central protease-sensitive hinge region (approximately 70 residues) and a C-terminal stable endostatin domain (approximately 180 residues). They also demonstrated that proteolytic release of endostatin can occur through several pathways, which may lead to a switch from a matrix-associated to a more soluble endocrine form.

PubMed Disclaimer

Cited by

Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
Anakha J, Dobariya P, Sharma SS, Pande AH. Anakha J, et al. Med Oncol. 2023 Dec 21;41(1):24. doi: 10.1007/s12032-023-02245-w. Med Oncol. 2023. PMID: 38123873 Review.
Endostatin inhibits VEGF-A induced osteoclastic bone resorption in vitro.
Sipola A, Nelo K, Hautala T, Ilvesaro J, Tuukkanen J. Sipola A, et al. BMC Musculoskelet Disord. 2006 Jul 13;7:56. doi: 10.1186/1471-2474-7-56. BMC Musculoskelet Disord. 2006. PMID: 16839420 Free PMC article.
Inhibitory effect of endostatin expressed by human liver carcinoma SMMC7721 on endothelial cell proliferation in vitro.
Wang X, Liu FK, Li X, Li JS, Xu GX. Wang X, et al. World J Gastroenterol. 2002 Apr;8(2):253-7. doi: 10.3748/wjg.v8.i2.253. World J Gastroenterol. 2002. PMID: 11925602 Free PMC article.
Dependence of cathepsin L-induced coronary endothelial dysfunction upon activation of NAD(P)H oxidase.
Zhang F, Zhang Y, Li PL. Zhang F, et al. Microvasc Res. 2009 Jun;78(1):45-50. doi: 10.1016/j.mvr.2009.03.006. Epub 2009 Apr 1. Microvasc Res. 2009. PMID: 19345232 Free PMC article.
A cryptic frizzled module in cell surface collagen 18 inhibits Wnt/beta-catenin signaling.
Quélard D, Lavergne E, Hendaoui I, Elamaa H, Tiirola U, Heljasvaara R, Pihlajaniemi T, Clément B, Musso O. Quélard D, et al. PLoS One. 2008 Apr 2;3(4):e1878. doi: 10.1371/journal.pone.0001878. PLoS One. 2008. PMID: 18382662 Free PMC article.

References

1. Cell. 1997 Jan 24;88(2):277-85 - PubMed
1. J Biol Chem. 1996 Nov 15;271(46):29461-7 - PubMed
1. Eur J Biochem. 1997 Jan 15;243(1-2):115-21 - PubMed
1. EMBO J. 1997 Mar 3;16(5):908-16 - PubMed
1. J Cell Biol. 1997 Aug 11;138(3):707-17 - PubMed

Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin - PubMed (original) (raw)